Horizon Therapeutics PLC
F:HPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (7.5), the stock would be worth €101.26 (8% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.2 | €110.2 |
0%
|
| 3-Year Average | 7.5 | €101.26 |
-8%
|
| 5-Year Average | 7.5 | €101.13 |
-8%
|
| Industry Average | 2.7 | €36.43 |
-67%
|
| Country Average | 2.3 | €31.66 |
-71%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
H
|
Horizon Therapeutics PLC
F:HPR
|
25.2B EUR | 8.2 | 67.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 6.7 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 6.2 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 5.9 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 8.4 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 4 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 10.5 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 3.4 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.3 |
| 70th Percentile | 4.2 |
| Max | 2 205.1 |
Other Multiples
Horizon Therapeutics PLC
Glance View
Horizon Therapeutics PLC, established in 2008 and headquartered in Dublin, has carved a unique niche in the biopharmaceutical industry by focusing on researching, developing, and commercializing medicines that address rare and rheumatic diseases. The company has embraced a patient-centric approach, aiming to improve the quality of life for individuals with conditions often overlooked by larger pharmaceutical companies. This dedication has resulted in a robust portfolio of medicines, including treatments for conditions like thyroid eye disease, chronic granulomatous disease, and urea cycle disorders. Horizon Therapeutics takes pride in its ability to identify and develop orphan drugs, leveraging innovative scientific methods and strategic acquisitions to enhance its offerings. The company generates its revenue by bringing its targeted therapies to market, often focusing on diseases with unmet medical needs. Horizon's business model capitalizes on its ability to navigate the intricate regulatory landscape surrounding rare disease treatments, allowing them to secure expedited approvals and launch therapies swiftly. By deepening its engagement with healthcare providers, patients, and advocacy groups, Horizon seeks to become an indispensable partner in the therapeutic process, thus driving consistent demand for its products. This strategic alignment not only boosts sales but also fortifies its market position, enabling Horizon Therapeutics to sustain its mission of transforming patients' lives through meaningful medicine.
